Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group

被引：1
|
作者：
Kwakman, J. J. M. [1 ]
Simkens, L. H. J. [2 ]
Van Rooijen, J. M. [3 ]
de Wouw, A. J. Van [4 ]
Loosveld, O. J. L. [5 ]
Creemers, G. J. M. [6 ]
Hendriks, M. P. [7 ]
Los, M. [8 ]
Van Alphen, R. J. [9 ]
Polee, M. B. [10 ]
Muller, E. W. [11 ]
Van der Velden, A. M. T. [12 ]
Van Voorthuizen, T. [13 ]
Koopman, M. [14 ]
Mol, L. [15 ]
Van Werkhoven, E. [16 ]
Punt, C. J. A. [1 ]
机构：
[1] Acad Med Ctr, Med Oncol, Amsterdam, Netherlands
[2] Maxima Med Ctr, Med Oncol, Eindhoven, Netherlands
[3] Martini Hosp, Med Oncol, Groningen, Netherlands
[4] VieCuri Med Ctr, Med Oncol, Venlo, Netherlands
[5] Amphia Hosp, Med Oncol, Breda, Netherlands
[6] Catharina Hosp, Med Oncol, Eindhoven, Netherlands
[7] Med Ctr Alkmaar, Med Oncol, Alkmaar, Netherlands
[8] St Antonius Hosp, Med Oncol, Nieuwegein, Netherlands
[9] TweeSteden Hosp, Med Oncol, Tilburg, Netherlands
[10] Med Ctr Leeuwarden, Med Oncol, Leeuwarden, Netherlands
[11] Slingeland Hosp, Med Oncol, Doetinchem, Netherlands
[12] Tergooi Hosp, Med Oncol, Hilversum, Netherlands
[13] Rijnstate Hosp, Med Oncol, Arnhem, Netherlands
[14] Univ Med Ctr Utrecht, Med Oncol, Utrecht, Netherlands
[15] Netherlands Comprehens Canc Ctr, Dept Data Management, Nijmegen, Netherlands
[16] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2017年 / 72卷
关键词：
D O I：
10.1016/S0959-8049(17)30099-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2BA
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): Results of a phase II study
    Barroso, S. A.
    Sanches, E.
    Ferreira, M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sotto-Mayor, C.
    Santo, J. Espirito
    San-Bento, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer
    Hurwitz, H
    Fernando, N
    Yu, DH
    Morse, M
    Blobe, G
    Gockerman, J
    Odogwu, L
    Mahon, M
    Truax, R
    Franklin, A
    ANNALS OF ONCOLOGY, 2005, 16 : 285 - 285
  • [43] First-line treatment for metastatic colorectal cancer (MCRC) patients (pts). Results of a randomized phase IIITMO study
    Bajetta, E.
    Di Bartolomeo, M.
    Ferrario, E.
    Beretta, E.
    Rabbi, C.
    Isa, L.
    Barone, C.
    Lo, S.
    Zilembo, Vullo N.
    ANNALS OF ONCOLOGY, 2005, 16 : 48 - 48
  • [44] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [45] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [46] Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
    Zeuli, M
    Nardoni, C
    Pino, MS
    Gamucci, T
    Gabriele, A
    Ferraresi, V
    Giannarelli, D
    Cognetti, F
    ANNALS OF ONCOLOGY, 2003, 14 (09) : 1378 - 1382
  • [47] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
    Kim, Seung Tae
    Hong, Yong Sang
    Lim, Ho Yeong
    Lee, Jeeyun
    Kim, Tae Won
    Kim, Kyu-Pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Chung, Ik-Joo
    Cho, Sang-Hee
    Lee, Kyung Hee
    Shin, Sang Joon
    Kang, Hye Jin
    Shin, Dong Bok
    Lee, Jae Won
    Jo, Sook Jung
    Park, Young Suk
    BMC CANCER, 2014, 14
  • [48] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
    Seung Tae Kim
    Yong Sang Hong
    Ho Yeong Lim
    Jeeyun Lee
    Tae Won Kim
    Kyu-Pyo Kim
    Sun Young Kim
    Ji Yeon Baek
    Jee Hyun Kim
    Keun-Wook Lee
    Ik-Joo Chung
    Sang-Hee Cho
    Kyung Hee Lee
    Sang Joon Shin
    Hye Jin Kang
    Dong Bok Shin
    Jae Won Lee
    Sook Jung Jo
    Young Suk Park
    BMC Cancer, 14
  • [49] Phase II study of bevacizumab in combination with capecitabine as first line treatment in elderly patients with metastatic colorectal cancer (MCC)
    Vrdoljak, E.
    Omrcen, T.
    Hrabar, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
    Vasile, E.
    Masi, G.
    Fornaro, L.
    Cupini, S.
    Loupakis, F.
    Bursi, S.
    Petrini, I.
    Di Donato, S.
    Brunetti, I. M.
    Ricci, S.
    Antonuzzo, A.
    Chiara, S.
    Amoroso, D.
    Andreuccetti, M.
    Falcone, A.
    BRITISH JOURNAL OF CANCER, 2009, 100 (11) : 1720 - 1724
12345